XML 101 R53.htm IDEA: XBRL DOCUMENT v3.25.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Narrative) (Details)
 1 Months Ended 12 Months Ended
Jun. 15, 2023
USD ($)
Mar. 31, 2023
USD ($)
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
product_target
$ / shares
shares
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2020
USD ($)
Feb. 29, 2020
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
General and administrative expense         $ 44,727,000 $ 61,167,000    
Deferred revenues         7,556,000 0    
Biogen MA, Inc.                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Change in estimate of transaction price, increase in revenue $ 127,100,000              
Biogen MA, Inc. | License and Service                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Fixed consideration               $ 204,600,000
Cumulative catch-up to expense   $ 2,500,000            
General and administrative expense         0 2,600,000    
Deferred revenues         0 $ 0    
Biogen MA, Inc. | Stock Purchase Agreement                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Sale of stock, number of shares issued in transaction (in shares) | shares       24,420,157        
Sale of stock, price per share (in dollars per share) | $ / shares       $ 9.2137        
Consideration received from sale of stock       $ 225,000,000        
Sale of stock, excess consideration received on transaction       79,600,000        
Collaboration agreement, equity issued       145,400,000        
Biogen MA, Inc. | Collaboration and License Agreement                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Proceeds from collaborators     $ 125,000,000 $ 125,000,000        
Number of neurological disease gene targets selected by counterparty (in product targets) | product_target       4        
Number of additional neurological disease gene targets | product_target       7        
Collaborative Arrangement Transaction Price $ 17,300,000              
Collaboration arrangement, commission fee, portion of gross proceeds, value             $ 7,000,000  
Collaborative agreement, percent of initial recognition       2.00%        
Contract with customer, asset, after allowance for credit Loss         $ 4,100,000